Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326740 · ClinicalTrials.gov registry record · Phase 3
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
A Phase 3 study, sponsored by Xoma (US).
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT02326740: Clinical Trial Phase 3 study, sponsored by Xoma (US).
NCT02326740 is a Phase 3 study that was terminated before completion, run by Xoma (US). The registered enrollment target is 9 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326740, a Phase 3 study, was terminated before completion, sponsored by Xoma (US).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
Interventions
- DRUG Placebo
- DRUG gevokizumab
- DRUG gevokizumab open-label
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 3 |
Why NCT02326740 stopped before completion
NCT02326740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02326740 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02326740 about?
NCT02326740 is a clinical study titled "An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum". The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
What is the current status of trial NCT02326740?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2014-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02326740?
The interventions under investigation include: Placebo (DRUG), gevokizumab (DRUG), gevokizumab open-label (DRUG).
Who is sponsoring clinical trial NCT02326740?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02326740's enrollment target sits among peer trials
9 1992nd of 2000 higher than 8 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia